Solitary Fibrous Tumor – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast...
Thelansis’s "Solitary Fibrous Tumor Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Solitary Fibrous Tumor treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Solitary fibrous tumor (SFT) is a rare mesenchymal neoplasm that can arise in various anatomical sites, including the pleura, soft tissues, and central nervous system. Most tumors harbor a NAB2–STAT6 gene fusion, a molecular hallmark that promotes abnormal transcriptional signaling. Clinical behavior ranges from slow-growing localized disease to tumors capable of recurrence or distant metastasis, sometimes years after initial treatment. Symptoms depend on tumor location and may include pain, pressure effects, or organ-specific dysfunction, while some lesions are detected incidentally. Complete surgical resection remains the preferred treatment for localized disease, with radiotherapy considered in selected cases. For unresectable or metastatic SFT, antiangiogenic agents such as pazopanib and sunitinib can provide disease control, while chemotherapy may be appropriate in selected settings, particularly for dedifferentiated tumors. Because late recurrence is possible and evidence for systemic treatments remains limited, long-term surveillance and specialist multidisciplinary care are essential.
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
1. Key Findings and Analyst Commentary
2. Disease Context
3. Epidemiology
4. Market Size and Forecast
5. Competitive Landscape
6. Unmet Need and TPP Analysis
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)
No snapshots available.
That depends on the file type you choose: the Excel epidemiology model, the Excel market forecast model with dashboard, and the full analyst report in PowerPoint with a PDF version.
Within 48 to 72 hours of purchase.
Yes. Choose EU5, G7 or G8, or pick individual markets in the panel.
Yes. Request a free sample to preview the scope and sample pages.
Yes. The forecast model is customizable, and our analysts can tailor the scope to your questions.
Yes. Inquire for bundle discounted pricing and we will send you exclusive pricing for the reports you need.
Choose the file type you want to purchase or request.
No file type found.
Select markets to include.
No markets match your search.
Not sure which report fits your question? Our team will point you to the right one.
Tell us what you are looking for and we will tailor the research to your indication, markets and questions.
Prefer to talk it through? Email clientsupport@thelansis.com
You asked for for covering . We will reply to .
Fill in your details and our expert consultants will get in touch with you.
Get a sneak peek at the latest Solitary Fibrous Tumor – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036 report
Our team will get in touch with you shortly about the Solitary Fibrous Tumor – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036 report.